Depline

Quick links to important sections

Depline

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Depline

Quick Facts

Property Description
Active ingredient Amitriptyline hydrochloride
Form Tablet or Film-coated tablet
Pharmacological class Tricyclic Antidepressant (TCA)
General purpose Mood stabilization and chronic nerve pain relief
Origin Synthetic compound

What Type of Medicine is Depline?

Depline is a branded, prescription-only medicinal product whose primary constituent is Amitriptyline hydrochloride. It is formally classified as a Tricyclic Antidepressant (TCA), positioning it within the specialized NEURO CNS therapeutic group, which modulates central nervous system function. This classification is clinically recognized for its established efficacy in managing neurological symptoms. The use of Amitriptyline in Depline’s formulation often targets scenarios where patients require both mood stabilization and management of chronic pain.

Depline: Composition, Form, and Chemical Origin

The core of Depline is the synthetic compound Amitriptyline, which is a Dibenzocycloheptenes derivative and a tertiary amine. The product is designed for oral administration, typically supplied as a tablet or a specialized film-coated tablet. This feature is intended to enhance the patient experience and protect the active ingredient during its passage through the digestive system. While Depline itself is usually a single active ingredient preparation, its status as an established compound means the same active ingredient is found in other preparations globally.

General Purpose and Action on Brain Chemicals (High-Level)

The functional principle of Depline involves inhibiting the reuptake of the monoamines Serotonin and Norepinephrine (Noradrenaline). This action effectively increases the concentration of these essential messengers available for communication between nerve cells. The resulting effect is utilized to provide general neurological support, helping to stabilize mood and reduce the persistent, intense signaling associated with various forms of chronic pain.

What side effects are possible with Depline?

Possible Side Effects and Safety Information: Depline

This information describes the documented safety profile and possible adverse effects associated with Depline (L-methylfolate), a medical food used under the supervision of a healthcare provider.

Serious and Clinically Significant Adverse Reactions

The most serious documented safety risk is a severe allergic reaction (hypersensitivity), which requires immediate medical attention. Signs may include difficulty breathing, hives, swelling of the face, lips, tongue, or throat, or a generalized rash.

Additionally, in rare instances, the use of L-methylfolate has been reported to potentially activate underlying or latent bipolar disorder (mania), or contribute to symptoms such as agitation, overactivity, excitement, confusion, or impaired judgment. Individuals with a history of bipolar disorder should be monitored carefully by their clinician.

Other Adverse Reactions and Warnings

As with many agents, some individuals may experience minor side effects, though the frequency of specific, less serious effects is generally reported to be similar to placebo in clinical studies. Documented non-severe reactions may include agitation, anxiety, and gastrointestinal issues such as nausea, abdominal discomfort, or diarrhea.

Population and Safety Considerations

  • Pre-existing Conditions: Inform your healthcare provider if you have a history of seizures/epilepsy, a history of vitamin B12 deficiency (pernicious anemia), or a history of bipolar disorder. Folate administration may mask the hematological signs of B12 deficiency while not addressing neurological progression.
  • Interactions: L-methylfolate may reduce the plasma levels of certain anticonvulsant medications (e.g., phenytoin, valproate). Consultation with a healthcare provider is essential before starting any new medications or supplements.
  • Overdose: An overdose is not expected to cause life-threatening symptoms, but any suspected overdose should be reported to emergency services or a poison control center immediately.

Depline is intended for use only under the direction of a healthcare provider as part of a complete management plan for the underlying condition. It should not be shared with others, and the brand or dosage strength should not be switched without medical advice.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory profile for Depline (Amitriptyline) overdose outlines a set of severe, potentially life-threatening manifestations, necessitating immediate medical attention upon any suspected ingestion higher than prescribed. The officially documented overdose presentations often involve a combination of Central Nervous System (CNS) effects and cardiovascular toxicity.

Documented Overdose Presentations and Scope Overdose is officially documented to present with signs across multiple physiological systems. CNS effects range from confusion, extreme drowsiness, and agitation to seizures, stupor, and coma. Physiological systems affected include the cardiovascular system, leading to irregular heart rate and low blood pressure (hypotension), and the autonomic nervous system, manifesting as dilated pupils and urinary retention. Ingestion of any amount by a child or any quantity higher than prescribed warrants immediate evaluation, as specified in regulatory documents.

Emergency Actions and Severity Classification Overdose is classified as severe and potentially life-threatening, particularly due to the risk of QRS complex prolongation and ventricular tachycardia. For this reason, official guidance mandates patients seek immediate medical attention and contact emergency medical services immediately. Treatment is primarily symptomatic and supportive, and official labeling confirms that no specific antidote is known. Continuous cardiac monitoring and repeated ECGs are required. Elderly patients are documented as having an increased risk for toxicity.

Therapeutic Uses of Depline

Depline (Amitriptyline) is generally applied across domains where additional symptomatic support is needed, relevant in contexts marked by increased discomfort or tension. Applications include several primary uses, such as Major Depressive Disorder (MDD), various forms of neuropathic pain, and the prophylaxis of migraine. This support contributes to easing the overall symptom load and may help improve day-to-day comfort.


Key Therapeutic Domains

This medication is commonly used in conditions characterized by periods of heightened symptoms. It is applied in addressing conditions like diabetic neuropathy or postherpetic neuralgia, where patients experience persistent, intense sensations such as burning or shooting discomfort. This supportive management is also relevant for easing distress and may support general well-being during symptomatic phases of MDD. Furthermore, it is applied in addressing conditions like nocturnal enuresis in children, and may be part of symptomatic management for the prophylaxis of chronic headaches.

“The goal of using this medication is to provide supportive relief when symptoms interfere with routine activities, contributing to easing the overall symptom load.”


Quick Fact Description
Relief for Pain May assist with managing symptoms related to chronic, long-standing neuropathic pain (e.g., shooting, burning).
Mood Support Can help address pervasive low mood and emotional distress symptoms associated with Major Depressive Disorder.
Preventative Use May be part of symptomatic management to help manage migraine headaches that interfere with daily functioning.

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Depline

Regulatory documentation defines specific patient populations and conditions that govern the use of Depline.

Classification Status & Requirements
Absolute Contraindications Use is prohibited for patients with a known hypersensitivity to the drug, pre-existing severe and uncompensated cardiovascular disease, or severe hepatic impairment (Child-Pugh Class C). Use is also contraindicated when taking or within 14 days of stopping a Monoamine Oxidase Inhibitor (MAOI).
Age-Based Eligibility Use is established for adults aged 18 to 65. Use in children and adolescents under 18 is not established due to insufficient data. Older adults (over 65) may use the medicine but require a specific lower initial dose.
Specific Limitations Patients with moderate renal impairment (creatinine clearance 30 to 60 mL/min) must adhere to a restricted maximum dosage. Patients with a history of seizure disorders require conditional use with close monitoring.
Pregnancy/Lactation Use during pregnancy is not recommended unless the benefit outweighs fetal risk. Use is also not recommended while breastfeeding, as the substance is known to be excreted into human milk.

Eligibility is determined by these official statements, which define non-negotiable exclusions and mandatory restrictions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information defines the interaction profile of Depline (Amitriptyline) through specific pharmacodynamic and pharmacokinetic constraints, which must be strictly observed.

Documented Interaction Patterns

Interaction Type Examples of Interacting Substances/Classes
Formally Contraindicated Combinations Monoamine Oxidase Inhibitors (MAOIs), Cisapride, and certain QTc-prolonging agents (e.g., Dronedarone, Pimozide).
Pharmacokinetic Exposure Increase Strong CYP2D6 inhibitors (e.g., Bupropion, Fluoxetine, Paroxetine, Quinidine) and Cimetidine.
Pharmacodynamic Additive Effects Alcohol, other CNS depressants (sedatives, narcotics), and serotonergic drugs (e.g., Triptans, Tramadol).
Timing-Separation Requirement A mandatory 14-day washout period is required when switching to or from an MAOI.

Co-administration with MAOIs is prohibited and requires the stated washout period to mitigate the risk of severe serotonergic reactions. This is a crucial regulatory constraint. Pharmacokinetic interactions involve enzyme metabolism; for instance, strong CYP2D6 inhibitors increase the medicine's plasma concentration, an effect documented in official prescribing information. The pharmacodynamic domain is characterized by additive effects that potentiate central nervous system depression, as noted with alcohol and other sedating agents. Population-specific notes indicate that individuals who are poor metabolizers of CYP2D6 may experience higher exposure levels.

Mechanism of Action

How Depline Works: Mechanism of Action


Dual Inhibition of Neurotransmitter Reuptake

Depline primarily acts within the domain of monoaminergic neurotransmission by selectively inhibiting the reuptake of both the Serotonin Transporter (SERT) and the Norepinephrine Transporter (NET) from the synaptic cleft. This foundational mechanism increases the concentration and prolongs the presence of active serotonin (5-HT) and norepinephrine (NE), influencing signal transduction patterns within key central nervous system pathways.


Modulating Central Regulatory Pathways

The resulting enhancement of dual monoamine signaling engages pathways within the central nervous system that govern monoaminergic circuit activity and descending pain signaling. Specifically, the increased norepinephrine availability modulates the activity of the descending pain inhibitory pathways, which modulate the transmission of afferent nociceptive signals. This systemic modulation alters activity patterns across central monoaminergic circuits, leading to a long-term adaptive change in postsynaptic receptor sensitivity and expression.

Dosage and Administration Information

Instruction Map: How to use Depline — Administration Guidelines

The administration of Depline (Amitriptyline hydrochloride) follows specific protocols regarding dosage, timing, and patient-specific adjustments as per established medical protocols.

Feature Guideline
Route of Administration The approved and standard route of administration is oral (tablet form).
Dosing Schedule Adult Outpatients: The maximum recommended daily dose is typically 150 mg. Inpatients under close supervision may receive up to 300 mg daily.
Pain Management Initial doses start at 10 mg to 25 mg daily, with maintenance generally in the range of 25 mg to 75 mg in the evening.
Timing in Relation to Meals Tablets can be taken with or without food. Administration of the entire dose is often recommended at bedtime due to the drug’s properties.
Age-Group Rules Older Adults: Treatment should begin with significantly lower dosages, such as 10 mg three times daily plus 20 mg at bedtime. Pediatric: A specific regimen for nocturnal enuresis (e.g., 25 mg to 50 mg daily for children 11 years and older) is defined.
Missed-Dose Rules If a dose is missed, it should be skipped if it is almost time for the next scheduled dose, as double doses are to be avoided.

Instruction Classifications (High-Level)

Classification Parameter
Administration Method Type Oral
Frequency Pattern Once daily or divided use.
Protocol Basis Established clinical guidelines
Use-Context Constraints Titration required (slow, incremental increase); Tapering required (gradual withdrawal).

Resulting Procedural Structure

Official step sequence:

  • Initiation: Start with the lowest initial dose specific to the patient's indication and age group.
  • Titration: Gradually increase the daily dose in small increments over several days until a satisfactory maintenance level is achieved.
  • Maintenance: Continue the established dose for a recommended minimum duration, such as three months, to help maintain relief.
  • Withdrawal: The medicine must be withdrawn gradually (tapered) over time.

Connection to the overall use protocol:

The administration protocol dictates a standardized oral use that commences with a low, carefully titrated dose, allowing for the flexibility of either divided or single, bedtime administration. Standard protocols establish specific maximum dose limits for various patient groups and clinical settings, such as the 150 mg outpatient maximum for adults. This structured approach, which includes the mandatory gradual withdrawal of the medicine, defines the pattern and duration of administration.

Recent Clinical Evidence

Research evidence / Overview of Studies for Depline (Amitriptyline)

The scientific understanding of Depline was developed through research that includes randomized controlled trials (RCTs), systematic reviews, and meta-analyses. The medicine has been observed in clinical evaluation for several decades, and the product was formally reviewed by regulators and retained its approved status. This overview summarizes the structure of this evidence as described in official and peer-reviewed scientific literature.


Evidence for use in Major Depressive Disorder (MDD)

Research exploring outcomes related to Major Depressive Disorder (MDD) was studied for in numerous short-term RCTs, many of which are older, conducted against a placebo or other antidepressant medicines. These trials primarily monitored outcomes related to systemic or functional imbalance using standardized rating scales over time intervals ranging from 3 to 12 weeks. Systematic reviews of these older trials reported how symptoms evolved in outcomes compared to an inactive substance. However, research exploring this area also documented that some trials had higher rates of study withdrawal.

Evidence is limited in characterizing the very long-term outcomes or outcomes reflecting daily functioning or activity level for MDD beyond the core symptom monitoring done in the trials. Furthermore, many of the core RCTs are considered older, meaning the detailed reporting on study methods, such as how blinding was maintained, may be less complete compared to contemporary trial standards.


Evidence for use in Chronic Neuropathic Pain

The research landscape for outcomes related to physical discomfort associated with chronic neuropathic pain (such as painful diabetic neuropathy or postherpetic neuralgia) relies on the evaluation of short-term RCTs, typically lasting from 4 to 12 weeks. These studies was observed in adults experiencing chronic pain and measured high-level outcomes like the patient-reported outcomes describing perceived discomfort and the percentage of participants who achieved a substantial change in pain scores.

Systematic reviews of this evidence often characterize the supporting research as moderate due to methodological factors. Sample sizes were modest in many of the included trials, and the follow-up durations were limited, preventing clear conclusions about sustained outcomes. Evidence quality varies across studies, and the data often lack the consistency typically seen in modern randomized trials.


Evidence for use in Migraine Prophylaxis

Research exploring outcomes related to the frequency of migraine attacks was conducted through randomized controlled trials and network meta-analyses. Studies focused on adults with episodic or chronic migraine headaches and tracked outcomes such as changes in monthly migraine day counts. While this use is not specifically FDA approved, major guideline bodies have included Depline in their summary of available research, often classifying the supporting evidence with a moderate level of certainty. Research findings from some studies are included in systematic reviews that contribute to the broader evidence landscape used by guideline bodies.


Evidence for Pediatric Use in Nocturnal Enuresis

Research exploring outcomes related to nocturnal enuresis (bedwetting in children) is based primarily on historical randomized controlled trials involving children aged 6 years and older. Studies monitored outcomes such as the achievement of a full response and the mean number of wet nights per week during the study period. Reviews classify this evidence as low because most of the trials are dated (often from the 1960s and 1970s) and may not adhere to current standards for methodological quality. Furthermore, systematic reviews consistently reported a high rate of recurrence (relapse) in outcomes once the study medication was discontinued, limiting insights into long-term sustainability.


Duration of Evidence and Follow-up Studies

The majority of controlled studies for Depline across conditions marked by functional limitations were designed for short-term, acute assessment, typically tracking outcomes over periods ranging from 3 to 12 weeks. While trials for depression have included long-term maintenance phases where symptom recurrence was observed, outcomes reflecting daily functioning or activity level are generally not well characterized by the existing body of randomized evidence. There is limited information for long-term outcomes, meaning certainty remains low regarding the patterns observed over many years.


Gaps in Evidence and Areas of Uncertainty

The research provides context, but not individual predictions. Evidence highlights what is known—and what is still uncertain. Key limitations noted by systematic reviews and regulatory evaluations include:

  • Evidence Quality Varies Across Studies: For pain and pediatric use, studies often have sample sizes that were modest and are noted as having evidence quality that varies across studies due to being older and pre-dating modern reporting standards.
  • Data for Certain Groups Remain Insufficient: Limited information for long-term outcomes is a general finding. Furthermore, subgroup findings are uncertain for specific complex populations, such as frail older adults or those with multiple co-existing medical conditions (comorbidities).
  • Long-Term Effects Are Not Fully Established: The evidence contributes to understanding symptom patterns over short-term follow-up durations, but there is a persistent lack of high-quality data that describes group patterns related to functional recovery and sustained remission over extended periods.

Frequently Asked Questions (FAQ)

Common questions about Depline (FAQ)

Q: Is Depline considered a strong medicine?

Official documents describe the medicine as a tricyclic antidepressant (TCA) and establish specific maximum daily doses that healthcare providers must follow. The initial dose prescribed is typically very low and is increased gradually over time. This approach allows for gradual adjustment toward a patient's established maintenance dose, as defined by the official administration protocols.


Q: How long does it usually take for Depline to start having an effect?

Studies and official information indicate that the full pattern of functional change and benefit is generally observed over several weeks to months of sustained use. While some changes in specific symptoms may begin to be noted within the first week of treatment, consistent use over the prescribed duration is defined by official documents as necessary for the clinical evaluation of its benefits.


Q: Does Depline have a risk of dependence or addiction?

Official sources describe the potential for physical dependence, which is noted in regulatory documents, particularly with prolonged treatment. For this reason, official guidance strictly requires the medicine to be withdrawn gradually, a process called tapering, to mitigate the occurrence of documented withdrawal reactions.


Q: Can Depline cause weight gain or weight loss?

Changes in body weight are reported in the official regulatory documentation. Both an increase in weight and, less commonly, a decrease in weight are listed among the documented side effects of the medicine.


Q: Does Depline affect sleep or cause insomnia?

According to the official product information, Depline can affect sleep patterns. It has been reported to cause drowsiness or sedation. The administration of the entire daily dose is often recommended at bedtime, a practice described in the official instructions. Conversely, insomnia or troubled sleep is also listed as a less common adverse effect.


Q: Can Depline interact with herbal supplements?

Regulatory guidance specifically contraindicates the use of the herbal supplement St John's wort (often taken for depression) with this medicine, as it can increase the risk of side effects. Consultation with a healthcare provider is noted as essential before taking this medicine alongside any herbal remedies or non-prescription supplements.


Q: What are the possible long-term effects of using Depline?

Most formal research focuses on short-term outcomes. However, official safety data notes that long-term use has been associated with certain effects, such as an increased risk of bone fractures and, for older adults, potential risk of confusion or cognitive decline. Official guidance emphasizes the importance of clinical supervision for patients receiving long-term treatment.


Q: What are the most commonly reported side effects of Depline?

Based on clinical trial data summarized in official documents, the most commonly reported side effects include drowsiness, dry mouth, constipation, dizziness, headache, and tremor. These effects often occur when first starting treatment.


Q: Can Depline affect blood pressure or heart rate?

Official documentation indicates that the medicine can influence the cardiovascular system. Documented adverse effects include fluctuations in blood pressure (orthostatic hypotension) and changes in heart rhythm, such as a fast or irregular heartbeat (tachycardia or arrhythmias).


Q: Can people with heart conditions use Depline?

Official information contraindicates the use of the medicine during the acute recovery period following a heart attack (myocardial infarction). It is also required to be used with extreme caution and monitoring in patients with pre-existing severe and uncompensated cardiovascular disease.


Q: What happens if Depline is taken for a longer period than recommended?

Official documents emphasize that the medicine should only be used according to the established prescription and duration. Use for longer periods than intended can increase the risk of physical dependence and the potential for long-term side effects.


Q: What is the difference between brand-name Depline and its generic equivalent?

The brand-name Depline contains the active ingredient amitriptyline hydrochloride. A generic equivalent contains the same active ingredient at the same strength, meeting the same strict quality and purity standards set by regulatory authorities.


Q: Can men and women expect different side effects from Depline?

Sexual side effects are documented for both men and women. Reports of changes to sex drive are noted for both genders, and specific side effects such as erectile dysfunction or ejaculation issues are also documented in males.


Q: Can Depline cause problems with sexual function?

Official documentation reports that the medicine can cause changes to sexual function. This may include an altered sex drive and, in males, specific problems such as erectile dysfunction or ejaculation issues.


Q: Can Depline affect lab test results?

The medicine can potentially affect certain lab test results. Official documentation notes that it may alter blood sugar levels and, less commonly, affect liver function test results. Clinical monitoring is often necessary when these tests are affected.


Q: Does Depline cause 'brain fog' or difficulty concentrating?

Regulatory documents list central nervous system effects that may contribute to these feelings. Potential adverse reactions include 'disturbed concentration,' 'confusion,' 'dizziness,' and 'somnolence' (drowsiness).


Q: Why do official sources recommend a gradual change when stopping Depline?

Official sources strictly recommend a gradual reduction (tapering) when stopping the medicine. This is required to minimize the risk of withdrawal reactions, which can include symptoms such as headache, nausea, and general physical discomfort.

How should Depline be stored and disposed of?

How to Store and Dispose of Depline?

This section details the officially documented requirements for the storage and disposal of Depline (Amitriptyline hydrochloride), based on regulatory labeling.

Requirement Type Official Instructions
Storage Temperature Store at controlled room temperature, typically 15 C to 30 C (59 F to 86 F). Do not freeze the product.
Protection Protect the medicine from excessive heat, light, and moisture. Keep the container tightly closed and in its original packaging.
Child Safety The medication must be kept strictly out of the sight and reach of children.

Regulatory authorities require that disposal of unused or expired Depline avoids the wastewater system. The preferred method is to utilize a drug take-back program. If a program is unavailable, specific instructions for mixing the medication with an undesirable substance before sealing and placing it in household trash must be followed. Disposal must comply with all national and local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Depline found in:

A-Z Index: